Preclinical and phase I clinical trial of blockade of IL-15 using Mikβ1 monoclonal antibody in T cell large granular lymphocyte leukemia

John C. Morris, John Edward Janik, Jeffrey D. White, Thomas A. Fleisher, Margaret Brown, Mitsuru Tsudo, Carolyn K. Goldman, Bonita Bryant, Michael Petrus, Lois Top, Cathryn C. Lee, Wendy Gao, Thomas A. Waldmann

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Twelve patients with T cell large granular lymphocyte leukemia and associated hematocytopenia were treated in a phase I dose-escalation trial with the murine monoclonal antibody Mikβ1. Mikβ1 identifies CD122, the β-subunit shared by the IL-2 and IL-15 receptors. At the doses administered in this study the antibody inhibited the actions of IL-15 on both natural killer and T cells and that of IL-2 when the intermediate-affinity IL-2 receptor was expressed. Mikβ1 treatment was not associated with significant toxicity or with the development of an immune response to the infused monoclonal antibody. At these doses of Mikβ1, >95% saturation of the IL-2/IL-15/3 receptor (CD122) on the surfaces of the leukemic cells was achieved. Furthermore, in seven patients this led to the down-modulation of the receptor from the surfaces of the leukemic cells. Nevertheless, no patients manifested a reduction in peripheral leukemic cell count or an amelioration of their hematocytopenia. This latter observation may reflect the fact that the monoclonal T cell large granular lymphocyte leukemia leukemic cells of the patients did not produce IL-2 or IL-15 or require their actions for cell survival. In light of the lack of toxicity and lack of immunogenicity of the antibody observed in the present study and the role for IL-15 in the pathogenesis of autoimmune diseases, clinical trials should be performed using the humanized version of Mikβ1 in groups of patients with human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis, rheumatoid arthritis, multiple sclerosis and refractory celiac disease.

Original languageEnglish (US)
Pages (from-to)401-406
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number2
DOIs
StatePublished - Jan 10 2006

Fingerprint

Large Granular Lymphocytic Leukemia
Interleukin-15
Clinical Trials, Phase I
Monoclonal Antibodies
Interleukin-2
Interleukin-15 Receptors
Interleukin-3 Receptors
Tropical Spastic Paraparesis
Natural Killer T-Cells
Antibodies
Interleukin-2 Receptors
Spinal Cord Diseases
Cell Surface Receptors
Celiac Disease
Autoimmune Diseases
Multiple Sclerosis
Rheumatoid Arthritis
Cell Survival
Cell Count
Observation

Keywords

  • Cytokine
  • IL-2/IL-15β receptor (CD122)
  • Natural killer cells

ASJC Scopus subject areas

  • General

Cite this

Preclinical and phase I clinical trial of blockade of IL-15 using Mikβ1 monoclonal antibody in T cell large granular lymphocyte leukemia. / Morris, John C.; Janik, John Edward; White, Jeffrey D.; Fleisher, Thomas A.; Brown, Margaret; Tsudo, Mitsuru; Goldman, Carolyn K.; Bryant, Bonita; Petrus, Michael; Top, Lois; Lee, Cathryn C.; Gao, Wendy; Waldmann, Thomas A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 2, 10.01.2006, p. 401-406.

Research output: Contribution to journalArticle

Morris, JC, Janik, JE, White, JD, Fleisher, TA, Brown, M, Tsudo, M, Goldman, CK, Bryant, B, Petrus, M, Top, L, Lee, CC, Gao, W & Waldmann, TA 2006, 'Preclinical and phase I clinical trial of blockade of IL-15 using Mikβ1 monoclonal antibody in T cell large granular lymphocyte leukemia', Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 2, pp. 401-406. https://doi.org/10.1073/pnas.0509575103
Morris, John C. ; Janik, John Edward ; White, Jeffrey D. ; Fleisher, Thomas A. ; Brown, Margaret ; Tsudo, Mitsuru ; Goldman, Carolyn K. ; Bryant, Bonita ; Petrus, Michael ; Top, Lois ; Lee, Cathryn C. ; Gao, Wendy ; Waldmann, Thomas A. / Preclinical and phase I clinical trial of blockade of IL-15 using Mikβ1 monoclonal antibody in T cell large granular lymphocyte leukemia. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 2. pp. 401-406.
@article{fa65e8e197db4162ae856d7b7140f4ff,
title = "Preclinical and phase I clinical trial of blockade of IL-15 using Mikβ1 monoclonal antibody in T cell large granular lymphocyte leukemia",
abstract = "Twelve patients with T cell large granular lymphocyte leukemia and associated hematocytopenia were treated in a phase I dose-escalation trial with the murine monoclonal antibody Mikβ1. Mikβ1 identifies CD122, the β-subunit shared by the IL-2 and IL-15 receptors. At the doses administered in this study the antibody inhibited the actions of IL-15 on both natural killer and T cells and that of IL-2 when the intermediate-affinity IL-2 receptor was expressed. Mikβ1 treatment was not associated with significant toxicity or with the development of an immune response to the infused monoclonal antibody. At these doses of Mikβ1, >95{\%} saturation of the IL-2/IL-15/3 receptor (CD122) on the surfaces of the leukemic cells was achieved. Furthermore, in seven patients this led to the down-modulation of the receptor from the surfaces of the leukemic cells. Nevertheless, no patients manifested a reduction in peripheral leukemic cell count or an amelioration of their hematocytopenia. This latter observation may reflect the fact that the monoclonal T cell large granular lymphocyte leukemia leukemic cells of the patients did not produce IL-2 or IL-15 or require their actions for cell survival. In light of the lack of toxicity and lack of immunogenicity of the antibody observed in the present study and the role for IL-15 in the pathogenesis of autoimmune diseases, clinical trials should be performed using the humanized version of Mikβ1 in groups of patients with human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis, rheumatoid arthritis, multiple sclerosis and refractory celiac disease.",
keywords = "Cytokine, IL-2/IL-15β receptor (CD122), Natural killer cells",
author = "Morris, {John C.} and Janik, {John Edward} and White, {Jeffrey D.} and Fleisher, {Thomas A.} and Margaret Brown and Mitsuru Tsudo and Goldman, {Carolyn K.} and Bonita Bryant and Michael Petrus and Lois Top and Lee, {Cathryn C.} and Wendy Gao and Waldmann, {Thomas A.}",
year = "2006",
month = "1",
day = "10",
doi = "10.1073/pnas.0509575103",
language = "English (US)",
volume = "103",
pages = "401--406",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "2",

}

TY - JOUR

T1 - Preclinical and phase I clinical trial of blockade of IL-15 using Mikβ1 monoclonal antibody in T cell large granular lymphocyte leukemia

AU - Morris, John C.

AU - Janik, John Edward

AU - White, Jeffrey D.

AU - Fleisher, Thomas A.

AU - Brown, Margaret

AU - Tsudo, Mitsuru

AU - Goldman, Carolyn K.

AU - Bryant, Bonita

AU - Petrus, Michael

AU - Top, Lois

AU - Lee, Cathryn C.

AU - Gao, Wendy

AU - Waldmann, Thomas A.

PY - 2006/1/10

Y1 - 2006/1/10

N2 - Twelve patients with T cell large granular lymphocyte leukemia and associated hematocytopenia were treated in a phase I dose-escalation trial with the murine monoclonal antibody Mikβ1. Mikβ1 identifies CD122, the β-subunit shared by the IL-2 and IL-15 receptors. At the doses administered in this study the antibody inhibited the actions of IL-15 on both natural killer and T cells and that of IL-2 when the intermediate-affinity IL-2 receptor was expressed. Mikβ1 treatment was not associated with significant toxicity or with the development of an immune response to the infused monoclonal antibody. At these doses of Mikβ1, >95% saturation of the IL-2/IL-15/3 receptor (CD122) on the surfaces of the leukemic cells was achieved. Furthermore, in seven patients this led to the down-modulation of the receptor from the surfaces of the leukemic cells. Nevertheless, no patients manifested a reduction in peripheral leukemic cell count or an amelioration of their hematocytopenia. This latter observation may reflect the fact that the monoclonal T cell large granular lymphocyte leukemia leukemic cells of the patients did not produce IL-2 or IL-15 or require their actions for cell survival. In light of the lack of toxicity and lack of immunogenicity of the antibody observed in the present study and the role for IL-15 in the pathogenesis of autoimmune diseases, clinical trials should be performed using the humanized version of Mikβ1 in groups of patients with human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis, rheumatoid arthritis, multiple sclerosis and refractory celiac disease.

AB - Twelve patients with T cell large granular lymphocyte leukemia and associated hematocytopenia were treated in a phase I dose-escalation trial with the murine monoclonal antibody Mikβ1. Mikβ1 identifies CD122, the β-subunit shared by the IL-2 and IL-15 receptors. At the doses administered in this study the antibody inhibited the actions of IL-15 on both natural killer and T cells and that of IL-2 when the intermediate-affinity IL-2 receptor was expressed. Mikβ1 treatment was not associated with significant toxicity or with the development of an immune response to the infused monoclonal antibody. At these doses of Mikβ1, >95% saturation of the IL-2/IL-15/3 receptor (CD122) on the surfaces of the leukemic cells was achieved. Furthermore, in seven patients this led to the down-modulation of the receptor from the surfaces of the leukemic cells. Nevertheless, no patients manifested a reduction in peripheral leukemic cell count or an amelioration of their hematocytopenia. This latter observation may reflect the fact that the monoclonal T cell large granular lymphocyte leukemia leukemic cells of the patients did not produce IL-2 or IL-15 or require their actions for cell survival. In light of the lack of toxicity and lack of immunogenicity of the antibody observed in the present study and the role for IL-15 in the pathogenesis of autoimmune diseases, clinical trials should be performed using the humanized version of Mikβ1 in groups of patients with human T cell lymphotropic virus I-associated myelopathy/tropical spastic paraparesis, rheumatoid arthritis, multiple sclerosis and refractory celiac disease.

KW - Cytokine

KW - IL-2/IL-15β receptor (CD122)

KW - Natural killer cells

UR - http://www.scopus.com/inward/record.url?scp=31044434393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31044434393&partnerID=8YFLogxK

U2 - 10.1073/pnas.0509575103

DO - 10.1073/pnas.0509575103

M3 - Article

C2 - 16387851

AN - SCOPUS:31044434393

VL - 103

SP - 401

EP - 406

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 2

ER -